Factor IXa (FIXa) 1 is a serine protease that participates in the intrinsic phase of blood coagulation (1, 2) . FIXa is derived from the zymogen FIX by limited proteolytic cleavage at Arg 145 -Ala 146 and Arg 180 -Val 181 mediated either by factor XIa (FXIa) or by factor VIIa/tissue factor (FVIIa/TF). FIXa catalyzes the activation of factor X (FX) by enzymatic hydrolysis of the Arg 52 -Ile 53 bond in the heavy chain. Maximal catalytic efficiency (k cat /K m ) of this reaction results from assembly of the FX activating complex (3) , which consists of FIXa, factor VIIIa (FVIIIa) (a nonenzymatic cofactor), and FX assembled on a procoagulant surface such as the activated platelet membrane. Assembly of the FX activating-complex is a result of surface localization of each of the protein components.
Surface localization of FIXa, FVIIIa, and FX results from interactions with high-affinity, specific binding sites on the procoagulant surface. A three-receptor model has been proposed whereby platelets expose distinct binding sites for FIXa, FVIIIa, and FX (4 -7). Occupancy of these binding sites is thought to promote the interactions among these proteins and facilitate assembly of functional FX activating complexes. In support of this model, FIXa has been found to bind to thrombinactivated platelets (4) , as have FVIIIa (5, 6) and FX (7) . FIXa has been found to bind to ϳ600 sites per platelet in the presence of FVIIIa and FX (K d ϭ 0.5 nM) as well as in their absence (K d ϭ 3 nM). Thus, one consequence of FIXa-FVIIIa interactions is an enhancement of FIXa surface binding affinity. In contrast, the FIX zymogen binds to a reduced number of sites (250 -300 sites per platelet, K d ϭ 3 nM), and neither its affinity nor stoichiometry is enhanced by the presence of FVIIIa and FX. FX binds to platelets (ϳ16000 sites per platelet, K d ϭ 300 nM) at a site shared with prothrombin (7) . FVIIIa has been found to bind to ϳ750 sites per platelet (K d ϭ 1.5 nM) with an increase in stoichiometry (1200 sites per platelet, K d ϭ 0.8 nM) upon addition of FIXa and FX (5, 6) . The rate of FX activation is closely correlated with the amount of surface-bound FIXa (8) . Further, surface-bound FX has been found to be the preferred substrate for the FX activating complex (9) . While informative with respect to the consequences of surface binding, these observations do not provide details regarding the mechanism of surface binding.
Investigations into the mechanism of FIXa surface binding have identified structural regions of FIXa that mediate surface interactions. Residues at the amino terminus of FIXa (the loop, residues 1-12) have been found to contain an interactive site that promotes binding to platelets (10, 11) , phospholipid vesicles (12) , and endothelial cells (13) . Experiments from our laboratory suggest that residues distinct from those contained within 1-12 are also important for binding to platelets and phospholipids (11, 14) . Residues contained within the second epidermal growth factor (EGF2)-like domain have been found to be important for surface binding and optimal rates of FX activation (15) . A chimeric protein containing the FX EGF2 domain in place of that of FIXa (FIXa FXEGF2 ) was found to bind to a reduced number of sites (175 sites per platelet) and with a reduced affinity K d(app) ϭ 65 nM) compared with wild type FIXa (FIXa WT ) (600 sites per platelet, K d ϭ 3 nM) (16) . FIXa FXEGF2 was also deficient in its FX activating activity (V max ϭ 3 pM FXa per min) compared with FIXa WT (V max ϭ 38 pM FXa per min) (16) . These results highlight the important contribution of the EGF2 domain to the surface-localization and catalytic properties of FIXa.
Our interest has been to further investigate the mechanism by which FIXa binds to surfaces and to understand the functional consequences of these interactions. We have prepared several chimeric proteins substituting various loops of the FIXa EGF2 domain with those of FVII. Our objective is to determine which loops of the FIXa EGF2 domain are important for platelet binding properties and for FX activation. We have previously described the purification, characterization, and the kinetic properties of FIXa EGF2 chimeric proteins in the presence of phospholipid vesicles (45) . In this report, we describe the platelet binding and kinetic properties of FIXa EGF2 chimeric proteins. We have identified residues contained within the sequence Cys 88 to Cys 109 that mediate surface binding and assembly of FX activating complexes on the platelet membrane.
EXPERIMENTAL PROCEDURES
Materials-Grade VII apyrase was purchased from Sigma. Pentex density gradient medium (35% w/v bovine serum albumin) was purchased from Bayer (Kankakee, IL). Sepharose CL-2B, fatty acid-free bovine serum albumin (BSA), para-aminobenzamidine, and heparin from porcine intestinal mucosa were purchased from Sigma. Carrierfree Na 125 I was obtained from Amersham Biosciences, Inc. Human FIX, human FX, human antithrombin III, and the FX activator from Russell's Viper (Vipera russeli) venom were purchased from Enzyme Research Laboratories (South Bend, IN). FXIa was purchased from Hematologic Technologies (Essex Junction, VT). High-purity recombinant human FVIII was obtained as a generous gift from Baxter Healthcare Corp. (Duarte, CA). Thrombin was purchased from Sigma. The chromogenic substrate S-2765 (N-benzlyoxy-carbonyl-D-arginyl-glycyl-L-arginine-para-nitroanalide-dihydrochloride) was purchased from Dia Pharma Group (Stockholm, Sweden).
Peptides-The following peptides were synthesized by the Protein Chemistry Laboratory (Dr. John Lambris) of the University of Pennsylvania (Philadelphia, PA) as described previously using 9-fluorenylmethyloxycarbonyl chemistry on an Applied Biosystems 430A Synthesizer and reverse-phase high pressure liquid chromatography purified to Ͼ99% homogeneity (7, 11) : thrombin receptor agonist peptide (SFLLRN-amide), a conformationally constrained ␥-carboxyglutamic acid ("Gla") peptide (CPGKLDEFVQPC) comprising Gly 4 -Gln 11 of FIX, a "scrambled" Gla peptide, and the EGF2 peptide (LDVTCNIKN-GRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAV) comprising Leu 84 to Val 128 of FIX. The EGF2 domain peptide contained 45 residues including six cysteines involved in disulfide bridges formed as in the native protein using a selective protection/deprotection strategy as previously reported by Yang, et al. (17) . Peptides were dissolved in deionized water to a final concentration of 100 g/ml in a flask containing a stir bar in order to refold the peptides containing cysteine residues. After the pH value was adjusted to 8.5 with NH 4 OH, the solution was allowed to stir at 5°C for at least 3 days. The solution was then lyophilized or, alternatively, peptides were reduced with dithiothreitol (1 mM) and alkylated with iodoacetamide (5 mM) as described previously (18) .
All peptides used in this study were examined by high-performance liquid chromatography (both reverse-phase and gel filtration) and all demonstrated a single homogenous peak. This demonstrates the presence of a single homogenous mixture of refolded peptides and not a mixed population of diverse polymers. The results are the same after reduction and alkylation of the same peptides. In addition, all peptides were examined for the presence of free sulfhydryl groups using the Ellman reagent, 5,5Ј-dithiobis-(2-nitrobenzoic acid). It was determined that there was less than 0.02 mol of free sulfhydryl per mol of peptide, which further verifies that these peptides were homogenous preparations.
Buffers-HEPES-Tyrodes buffer (HT): 15 mM HEPES (N-(2-hydroxyethyl)-piperazine-NЈ-(2-ethanesulfonic acid), 126 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 375 M NaH 2 PO 4 , and 5.6 mM glucose. The pH of HT for platelet isolation was 6.5, for enzyme assays the pH was 7.4. HT was supplemented with BSA (2 mg/ml or 0.5 mg/ml) and CaCl 2 ( Isolation of Platelets-Washed, gel-filtered platelets were prepared according to the following protocol (20 -22) . Donor blood was collected into tubes (50 ml) containing 7 ml of the following buffer: trisodium citrate (25 g/L), citric acid (15 g/L), and glucose (20 g/L). The blood was centrifuged (200 ϫ g) to separate platelet-rich plasma. The platelet-rich plasma was collected and supplemented with apyrase to a final concentration of 0.5 units/ml with incubation at 37°C for 15 min. The plateletrich plasma was layered gently over a 17.5% (w/v) albumin solution (0.8 ml prepared by addition of 0.4 ml each of HT, pH 6.5, supplemented with BSA (2 mg/ml) and Pentex density gradient medium (35% w/v BSA)) containing apyrase (2.5 units/ml) in a 15-ml polystyrene tube (Becton Dickinson, Franklin Lakes, NJ). The platelets were pelleted by centrifugation (800 ϫ g), resuspended in 10 ml of HT (pH 6.5) supplemented with BSA (2 mg/ml). The platelet suspension was layered gently over 1 ml of the 17.5% albumin solution described above, and the platelets pelleted again (800 ϫ g). The platelets were resuspended in 2 ml of HT (pH 6.5) supplemented with BSA (2 mg/ml) and loaded onto a Sepharose CL-2B column (50 ml) pre-equilibrated with HT supplemented with BSA (2 mg/ml). Platelets were eluted from the column with HT supplemented with BSA (2 mg/ml). The most platelet-rich fractions as judged by visual inspection were pooled, and the platelet concentration was determined electronically using a Coulter Counter (Coulter Electronics, model ZBI, Hialeah Fl). Platelets were maintained at 37°C and used within 3-4 h after isolation.
Equilibrium Binding Studies-In a typical binding experiment, platelets (3-4 ϫ 10 8 platelets/ml) were incubated in HT supplemented with BSA (2 mg/ml), 5 mM CaCl 2 , and mixtures of labeled and unlabeled FIXa proteins or peptides as described previously (4, 11) . In brief, all binding experiments were performed in 1.5-ml Eppendorf plastic centrifuge tubes at 37°C for 20 min. After incubation, aliquots (100 l) were removed and centrifuged (at 12,000 ϫ g in a Beckman Microfuge E through a mixture of silicone oils (Dow-Corning 500 and Dow Corning 200 mixed 4:1, vol:vol) to separate platelets from unbound proteins (4). The 125 I content in both the platelet pellets and the supernatants was determined by counting ␥-emission in a Wallac ␥ counter (Gaithersburg, MD) using (23) was used to determine the inhibition constants as previously published (18) . Binding experiments were performed both in the absence and presence of FVIIIa and FX.
Assay of FXa-FXa was assayed by hydrolysis of the FXa-specific chromogenic substrate S-2765. FXa (50 l) was added to wells of a microtiter plate, and S-2765 (50 l) was added to a final concentration of 350 M. Change in absorbance at 405 nm was monitored immedi-ately. Unknown FXa concentrations were determined by comparison to a standard curve prepared with known dilutions of FXa.
Determination of K m(app) and V max on Platelets in the Absence of FVIIIa-FIXa proteins were added to 5 nM in reaction vessels containing platelets (3 ϫ 10 8 platelets/ml) in HT supplemented with BSA (2 mg/ml) and 5 mM CaCl 2 . Platelets were activated by addition of the peptide SFLLRN-amide to 5 M. FIXa proteins were preincubated with the activated platelets at 37°C for 10 min. The reactions were initiated by addition of FX to the indicated final concentrations. After 20 min at 37°C, the reactions were stopped by addition of EDTA to 10 mM. FXa was determined as described above. Velocity of FXa generation (nM FXa/min) was plotted as a function of input FX concentration (nM). Kinetic constants were determined as described below.
Determination of K m(app) and V max in the Presence of FVIIIa-FIXa proteins were added to 1 nM in reaction vessels containing platelets (5 ϫ 10 7 platelets/ml) in HT supplemented with BSA (2 mg/ml) and 5 mM CaCl 2 . Platelets were activated by addition of the peptide SFLLRNamide to 5 M. FIXa proteins were incubated with the activated platelets at 37°C for 6 min. FVIII was activated to FVIIIa (5 units/ml final) by thrombin (0.1 units/ml) for 1 min at 37°C immediately before addition to the reaction vessels. The reactions were initiated by addition of FX to the indicated final concentrations. After 2 min at 37°C, the reaction was stopped by addition of EDTA to 10 mM. FXa was determined as described above. Kinetic constants were determined as described below.
Determination of K d(app) and Maximal Velocity Observed in the Presence of Saturating FIXa (V max
9 ) in the Absence of FVIIIa-FIXa proteins were titrated into reaction vessels (to the indicated final concentrations) containing platelets (3 ϫ 10 8 platelets/ml) in HT supplemented with BSA (2 mg/ml) and 5 mM CaCl 2 . Platelets were activated by addition of the peptide SFLLRN-amide to 5 M. FIXa proteins were preincubated with the activated platelets at 37°C for 10 min. The reactions were initiated by addition of FX to 250 nM. After 20 min at 37°C, the reactions were stopped by addition of EDTA to 10 mM. FXa was determined as described above. Kinetic constants were determined as described below.
9 ) in the Presence of FVIIIa-FIXa proteins were titrated into reaction vessels (to the indicated final concentrations) containing platelets (5 ϫ 10 7 platelets/ml) in HT supplemented with BSA (2 mg/ml) and 5 mM CaCl 2 . Platelets were activated by addition of the peptide SFLLRN-amide to 5 M. FIXa proteins were incubated with the activated platelets at 37°C for 6 min. FVIII was activated to FVIIIa (5 units/ml final concentration) by thrombin (0.1 units/ml) for 1 min at 37°C immediately before addition to the reaction vessels. The reactions were initiated by addition of FX to 250 nM. After 2 min at 37°C, the reactions were stopped by addition of EDTA to 10 mM. FXa was determined as described above. Kinetic constants were determined as described below.
Determination of Kinetic Constants-For K m(app) and V max determinations, velocity of FXa generation (nM FXa/min) was plotted as a function of input FX concentration (nM). K m(app) and V max were calculated by fitting the data to the Michaelis-Menten equation. For K d(app) and V max 9 determinations, velocity of FXa generation (nM FXa/min) was plotted as a function of input FIXa concentration (nM). K d (app) and V max 9 were calculated from the following equation modified from the Michaelis-Menten equation:
is the apparent dissociation constant, and V max 9 is the velocity observed at saturating FIXa concentration.
Calculation of k cat -Turnover number (k cat ) is defined as mol FXa generated per mol of surface-bound FIXa per second. Mol FXa generated was calculated from the V max (nM FXa/min), mol surface-bound FIXa was calculated from the determined K d values for the given set of reaction conditions and the input FIXa protein concentration. B max was determined from the platelet concentration and the determined binding stoichiometry for each FIXa protein.
Statistical Method-Between group differences were tested for statistical significance using analysis of variance followed by pair-wise comparisons with the Bonferroni adjustment procedure for multiple comparisons maintaining an experiment-wise Type 1 error level of 0.05 (24) .
RESULTS
We were interested to determine the contribution of residues within the EGF2 domain of FIXa to platelet binding and activation of FX. Chimeric proteins (FIXa FVIIEGF2 , FIXa loop1 , FIXa loop2 , and FIXa loop3 ) were prepared by substituting residues of the FIXa EGF2 domain with the homologous residues of FVII. Point mutant proteins (FIXaR94D and FIXa loop1 G94R) were designed to address the contribution of Arg 94 present within loop 1 of the EGF2 domain. These proteins were purified and characterized as described previously (45) . Kinetic analyses of the various FIXa proteins identified loop 1 (residues 88 -99) and loop 2 (residues 95-109) as important for binding affinity to phospholipid vesicles. Arg 94 was found to be unnecessary for the kinetic properties assayed. In the present study, we characterized these residues with respect to their contribution to platelet binding affinity and stoichiometry, and activation of FX on the surface of activated platelets.
The chimeric proteins FIXa loop1 and FIXa loop2 were previously found to be deficient in their affinity for phospholipid vesicles as measured by an increased K d(app) (45) . Here, we determined the platelet binding properties of FIXa loop1 , FIXa loop2 , and FIXa loop3 . FIX proteins were labeled with 125 I, activated with FXIa, and tested for their ability to bind to platelets in the absence of FVIIIa and FX using equilibrium binding assays. As shown in Fig. 1 and Table I , FIXa loop1 and FIXa loop2 were deficient in platelet binding that was manifested in both a decreased affinity (increased K d ) and a reduced stoichiometry. FIXa WT and FIXa loop3 displayed normal binding properties (Table I ) when compared with plasma-derived FIXa (FIXa N ). Addition of FVIIIa and FX to the binding reaction was not sufficient to correct the binding deficiencies of FIXa loop1 and FIXa loop2 (Table I) .
The effects of the chimeric substitutions and point mutations on FX activation using platelets as a reaction surface were examined. Surface occupancy of platelet binding sites by FIXa was found to have a high correlation with rate of FX activation (8) . It was of interest to determine whether the FIXa loop1 and FIXa loop2 proteins were deficient in FX activation in conjunction with their binding deficiencies. Titration of FIXa proteins into the reaction was used to determine a K d(app) value (FIXa concentration resulting in half-maximal rate of FX activation) as well as a V max 9 value (maximum rate of FX activation in the presence of saturating FIXa concentration). K d (app) and V max 9 values were determined from the isotherms shown in Fig. 2 and are reported in Table II . In addition to the proteins studied above, we also examined the FIXaR94D, FIXa FVIIEGF2 , and FIXa loop1 G94R proteins in this assay. As shown in Fig. 2B and Table II, normal properties with respect to FX activation suggesting that neither Arg 94 nor loop 3 residues (111-124) are important for platelet binding and FX activation. FIXa loop1 and FIXa loop2 also had a reduced V max 9 of FX activation in the presence of platelets consistent with their reduced platelet-binding stoichiometry.
The kinetic properties of the various FIXa proteins were also determined when FVIIIa was included in the assay mixture. FIXa titrations were repeated in the presence of excess FVIIIa (Fig. 3) . K d(app) and V max 9 values for each of the FIXa proteins were determined from the isotherms and are reported in Table  II . The FIXa FVIIEGF2 , FIXa loop1 , FIXa loop2 , and FIXa loop1 G94R proteins were found to have increased K d(app) values that were not corrected by the addition of FVIIIa. Again, FIXa loop3 and FIXaR94D were entirely normal in this assay. Collectively, these data support the hypothesis that the EGF2 domain is responsible for platelet binding independent of the presence or absence of FVIIIa. We find no evidence for impaired interaction with FVIIIa for any of the FIXa proteins since all FIXa proteins showed normal fold decreases in K d , K d(app) , and normal fold increases in V max 9 upon the addition of FVIIIa consistent with previous findings (4, 16) .
To confirm that the kinetic deficiencies of FIXa loop1 and FIXa loop2 were a result of impaired surface binding properties and not a result of deficient interactions with FX (in either the presence or absence of FVIIIa), we determined K m(app) and V max values for each of the FIXa proteins. FX was titrated in 7 platelets/ml. Platelets were activated by addition of the thrombin receptor agonist peptide (SFLLRN-amide) to 5 M. After 5 min at 37°C, FVIII was activated to FVIIIa (for 1 min) and immediately added to the reaction vessels to 5 units/ml final concentration. After 1 min, the reactions were initiated by addition of FX to 250 nM. After 2 min, the reactions were terminated by addition of EDTA to 10 mM. FXa was measured as described above. the presence of platelets and either the absence (Fig. 4) or the presence of FVIIIa (Fig. 5) (Table IV) . k cat values (sec Ϫ1 ) are calculated as mol FXa formed per second per mol surface-bound FIXa (not total input FIXa concentration). It is clear that the FIXa mutant proteins used in this investigation are catalytically normal when bound to the platelet surface and that the consequence of the loop 1 and loop 2 substitutions is to reduce the ability of these proteins to bind to the surface.
Rate of FXa generation (nM FXa/min) is plotted versus input FIXa concentration (nM)
The next objective was to determine the specific function of the FIXa EGF2 domain. These experiments strongly suggest that the EGF2 domain residues 88 -109 are important for platelet binding and FX activation. However, our results are consistent with at least two distinct functions for the EGF2 domain whereby it can promote the surface binding of FIXa. One possibility is that the EGF2 domain is responsible for contacting a binding site on the surface. Alternatively, the FIXa EGF2 domain can promote surface binding by maintaining a specific tertiary structure of the FIXa molecule. To determine whether the FIXa EGF2 domain is responsible for directly mediating surface binding, we tested a peptide derived from the FIXa EGF2 domain amino acid sequence (Leu 84 -Val 128 ) as a competitive inhibitor of FIXa platelet binding. If the function of the EGF2 domain is only to maintain the tertiary structure of FIXa, then the peptide should fail to inhibit the binding of 125 I-labeled FIXa to the platelet surface. However, if the EGF2 domain contains a surface-interactive site, we predicted that the EGF2 peptide should inhibit the binding of The reduced and alkylated EGF2 domain peptide was ineffective as an inhibitor (data not shown) as was a control scrambled peptide based the FIX Gly 4 -Gln 11 sequence (Fig. 6) , whereas a conformationally constraining Gly 4 -Gln 11 peptide was a potent inhibitor of FIXa binding to activated platelets (11, 16) . Moreover, we observed a 50% reduction in V max when the EGF2 peptide (1 M) was used as an inhibitor of FX activation in the presence of FVIIIa and activated platelets (data not shown). These results strongly suggest that the EGF2 domain of FIXa is responsible for mediating the platelet binding of FIXa.
DISCUSSION
In this study we have characterized residues 88 -109 in the FIXa EGF2 domain with respect to platelet binding and enzymatic activation of FX. From our investigation, we conclude that the EGF2 domain is responsible for mediating the binding of FIXa to activated platelets. This conclusion is justified based on the internally consistent results from three different experimental strategies: equilibrium binding studies, kinetics of FX activation, and peptide competition binding studies. This previously unrecognized platelet-interactive site has been further localized within residues 88 -109.
The physiological importance of intrinsic FX activation toward hemostasis has long been recognized (2, 25) . Platelets mediate this important step in blood coagulation by promoting the membrane surface localization of FIXa, FVIIIa, and FX (4 -7, 26). Surface localization of these proteins promotes assembly of functional FX activating complexes (3, 8, 9, 27 ). The FX activating complex is a potent activator of FX resulting in an ϳ20 million-fold increase in the catalytic efficiency (k cat /K m ) of FX activation versus that of FIXa in the absence of a reaction surface and the cofactor (3). Complex assembly requires that FIXa be localized on a suitable procoagulant surface.
The interaction of FIXa with procoagulant surfaces has been investigated for many years. These investigations have primarily focused on the contribution of the Gla domain to interactions with the phospholipid component of biological membranes. Indeed, there is much support for the hypothesis that the Gla domain is important for physiological activation of FX (2, 12, 14, 25, 28, 29) . Patients with the bleeding tendency hemophilia B have been identified that are associated with point mutations within the Gla domain (30) . The isolated Gla domain prepared by chemical synthesis has been found to bind to phospholipids (12, 28) . Other investigations have implicated the Gla domain for interactions with FVIIIa as well (29) . However, FIX molecules in which the Gla domain was removed by limited proteolysis or contained chemically modified Gla residues retained the ability to bind to platelets (albeit with reduced affinity) and activate FX (14) indicating that the Gla domain is not solely responsible for FIX(a) membrane interactions. In contrast to the well studied Gla domain, the functional contributions of the EGF-like domains (EGF1 and EGF2) have not been thoroughly investigated.
The importance of the EGF-like domains for FIX(a) procoagulant activity has been suggested by the occurrence of mutations within these domains that are associated with hemophilia B (30) . Investigations into the function of EGF1 have implicated it for a number of functions including FX binding (31) (32) (33) , a role in activation by FVIIa/TF (34), and a structural role for FVIIIa binding (35, 36) . Our lab has found no evidence that EGF1 is responsible for mediating surface binding (37) . Until recently, there has been little investigation into the function of the EGF2 domain; however preliminary investigation suggested an important contribution for the EGF2 domain. A FIX chimeric protein where EGF1 and EGF2 of FIX were replaced by those of FX retained only 4% clotting activity compared with plasma-derived FIX (whereas the EGF1 substituted protein was normal) (38) . Our investigation into the functional contribution of the EGF2 domain using a FIX chimeric protein where the EGF2 domain of FX was replaced by that of FX strongly implicated it for surface binding (15, 16) . Because surface-localization of FIXa is necessary for optimal rates of FX activation, the EGF2 domain warranted further investigation.
We prepared several FIXa proteins to test the contributions of various residues within the EGF2 domain toward platelet binding. Previous investigation identified loop 1 residues (88 -99) and loop 2 residues (95-109) as important for binding affinity to phospholipids containing phosphatidylserine (45) . The chimeric proteins appeared to be folded normally since kinetic constants (K m , V max , and EC 50 FVIIIa) were entirely normal compared with control proteins. We further characterized the contribution of Arg 94 utilizing two point mutations FIXaR94D and FIXa loop1 G94R. The data presented here are most consistent with a model in which the residues 88 -109 (but not Arg 94 ) within the FIXa EGF2 domain are responsible for mediating binding to surfaces (either phospholipid vesicles or activated platelets).
Synthetic phospholipid vesicles have been utilized as a model system for the physiologic membrane primarily responsible for intrinsic FX activation, the activated platelet (26) . It is, therefore, not surprising that the properties of the FIXa proteins on activated platelets are mimicked by those on phospholipid vesicles. FIXa proteins that showed normal kinetics in the presence of phospholipids (FIXa loop3 , FIXaR94D) were again found to be normal with respect to their platelet binding properties and their platelet-mediated FX activation. FIXa proteins that were found to have deficient phospholipid binding properties (FIXa FVIIEGF2 , FIXa loop1 , FIXa loop2 , and FIXa loop1 G94R) were also found to be deficient in platelet binding properties as well.
We observed good agreement with K d values obtained from binding studies (Table I) and K d(app) values determined from kinetic studies of FIXa titrations (Table II) . Thus substitutions that result in loss of binding affinity have generated consistent results using two different experimental approaches. The loss of affinity observed for the FIXa loop1 and FIXa loop2 proteins is likely to be a result of loss of specific residues of FIXa that are responsible for mediating interactions with the platelet surface. Loss of affinity resulting from either defective protein folding or defective interactions with FVIIIa or FX is not supported by our observations. First, we observe a loss of surface binding affinity in the absence of FVIIIa and FX. Second, determined values for K m and k cat are strongly supportive of normal binding and cleavage of FX. We observed normal fold increases in k cat (Table IV) upon addition of FVIIIa to reactions suggesting productive interactions with the cofactor. We also observed normal fold increase in affinity (fold decrease in (Tables I and II) , again suggesting normal interactions with FVIIIa. Furthermore, molecular modeling of the FIXa proteins revealed no predicted gross structural abnormalities when compared with known structural data (39) . These properties would not be expected of misfolded proteins.
The loss of binding stoichiometry of FIXa loop1 and FIXa loop2 (Table I) is not readily explained. These data are consistent with the presence of more than one class of binding site on the platelet surface. The presence of at least two classes of binding sites on the platelet surface has been supported by other investigations from our laboratory (11, 16) . However, the contribution of the EGF2 domain to binding each of these classes of sites is not clear since an overall loss of affinity is observed yet some sites seem completely inaccessible to the EGF2 chimeras. Thus the EGF2 domain may make differential contributions to each class of sites. However, once the chimeric proteins are bound to the surface, they are entirely normal with respect to their catalytic properties as measured by k cat values and stimulation of k cat by FVIIIa. Thus, the accessible sites for the FIXa loop1 and FIXa loop2 proteins appears to be capable of supporting assembly of functional FX activating complexes.
The properties of these proteins suggested that Arg 94 was not essential for surface binding affinity despite its presence within the sequence of 88 -109. These observations were in contrast to our predictions since other studies have suggested that Arg 94 is important for the tertiary structure of FIXa and promotes its normal interactions with FVIIIa (40 Finally, our studies with the EGF2 domain-derived peptide are a strong indicator that the EGF2 domain of FIXa is respon- sible for direct binding to the platelet surface. The EGF2 domain is thought to be important for maintaining the structural integrity of FIXa in such a way as to promote normal assembly of FX activating complexes (39 -42) . It was therefore a strong possibility that the consequences of mutations within EGF2 could cause structural alterations of FIXa and reduce its surface binding affinity. However, our peptide competition data are a strong indication that, in addition to structural functions, the EGF2 domain mediates the binding of FIXa to the surface. The fact that the EGF2 domain peptide (Leu 84 -Val 128 ) competes with 125 I-labeled FIXa for binding to the activated platelet surface is evidence that the EGF2 domain is responsible for contact with some platelet membrane component. That the peptide is an effective inhibitor in the absence of added FVIIIa, and FX is strong evidence that the EGF2 domain is responsible for direct contact with the membrane and is not responsible for interaction with either FVIIIa or FX. Interestingly, a peptide based on the FVII EGF2 domain was an effective inhibitor of FVIIa interaction with tissue factor (43) , and murine EGF has been found to associate with phospholipids (44) thus supporting the hypothesis that EGF2 of FIXa mediates surface binding.
Our investigation has identified a novel region of FIXa (residues 88 -109) that was previously not recognized for its contribution to FIX(a) functions. Here we report that the EGF2 domain is responsible for surface binding and assembly of functional FX activating complexes. Further, the functional deficiencies of FIXa loop1 and FIXa loop2 provide at least one causative mechanism for dysfunctional FIX proteins resulting from mutations within residues 88 -109. Thus, residues 88 -109 may be shown to be important for FIXa functions in vivo. It would be expected from our results here that FIXa loop1 and FIXa loop2 proteins should have a reduced ability to correct the clotting time in hemophilic dogs, which have been used previously to compare the in vitro properties of FIX proteins to those in vivo (42) . That the FIXa chimeric proteins retain platelet binding properties indicate that other regions of FIXa are also responsible for binding to the membrane (notably residues Gly 4 -Gln 11 in Gla domain and possibly other domains). The contribution of FIXa's various structural domains to surface binding and assembly of FX activating complexes should be investigated further.
